[{"begin": 192, "end": 214, "text": "of Parkinson's disease", "tokenized_text": "of Parkinson ' s disease", "type": "title", "id": 0}, {"begin": 216, "end": 269, "text": "Clinical and Experimental Pharmacology and Physiology", "tokenized_text": "Clinical and Experimental Pharmacology and Physiology", "type": "venue", "id": 1}, {"begin": 0, "end": 63, "text": "Leaver, K., Allbutt, H., Creber, N., Kassiou, M., Henderson, J.", "tokenized_text": "Leaver , K . , Allbutt , H . , Creber , N . , Kassiou , M . , Henderson , J .", "type": "authors", "id": 2}, {"begin": 65, "end": 69, "text": "2008", "tokenized_text": "2008", "type": "year", "id": 3}, {"begin": 72, "end": 191, "text": "Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model", "tokenized_text": "Neuroprotective effects of a selective N - methyl - D - aspartate NR2B receptor antagonist in the 6 - hydroxydopamine rat model", "type": "title", "id": 4}]